PregVax: Plasmodium vivax Infection in Pregnancy
The PregVax project is a four-year collaborative project aimed at addressing knowledge gaps in pregnancy and vivax malaria
- Website
- https://pregvax.isglobal.org
Approximately 25 million pregnant women exposed yearly to malaria live in areas where Plasmodium vivax is endemic. While the effects of falciparum malaria in pregnancy have been well characterised and are responsible for considerable maternal and infant morbidity and mortality, surprisingly little is known about the impact of P. vivax infection during gestation.
Malaria in pregnancy was prioritised by the 7th Framework Program of the European Commission. To fill the knowledge gaps of vivax malaria in pregnancy, the PregVax study carried out a cohort observational study in pregnant women in five P. vivax endemic countries, Brazil, Colombia, Guatemala, India, and Papua New Guinea, broadly representing most of the world's P. vivax infections.
Around ten thousand pregnant women were enrolled by the five sites in total at the time of routine antenatal care visits and followed-up at the health facility until delivery.
Main Objectives
The main objective of the PregVax study is to describe the epidemiological and clinical features of P. vivax malaria in pregnancy. The PregVax study will also determine if there are pregnancy-specific immune responses and characterize, genotypically and phenotypically, parasites of the placenta.
About Pregvax
Pregvax is a project of The Clinic Foundation.
It is funded by:
-Ministry of Economy and Competitivenes, Government of Spain
-7th EU Framework Program (FP7).
It belongs to the Malaria in Pregnancy Consortium.
Our Team
Principal Investigator
-
Clara Menéndez Santos
ISGlobal team
-
Azucena Bardají Associate Research Professor -
Carlota Dobaño Research Professor -
Alfredo Mayor Research Professor -
Jaume Ordi Research Professor -
MIREIA PIQUERAS Project Manager -
Hernando Del Portillo Obando
Other projects
R21 AI151459-01A1
Longitudinal Antibody Profiles Correlated with Protection from Malaria in Malawi
BASEMALVAC
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
GlycoTargets
New antimalarial therapies targeting the glycosylation pathways of ‘Plasmodium falciparum’
Evaluación de la eficacia del ácido acetilsalicílico a dosis bajas en la prevención de los efectos maternos y perinatales adversos en mujeres embarazadas infectadas por el SARS-CoV-2
PROTECT
PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa
CLIMSOCTRYPBOL
Insight on climate and social participatory research for integral management of vectorborne zoonosis caused by Trypanosoma cruzi and Leishmania spp. in the Bolivian Gran Chaco.
VaMonoS
Unravelling the heterogoneity and function of monocytes in vaccination and immunity to malaria
VivaxEVTalk
Extracellular Vesicles as Intercellular Communicators and Biomarkers of Cryptic Erythrocytic Infections in Plasmodium vivax malaria
